May-19 -

Brain Group

EORTC 1320 – Trabectedin for recurrent grade II or III meningioma.

A randomized phase II study of the EORTC Brain Tumor Group.

EORTC study assessed the effectiveness of an anti-tumour drug, trabectedin, for grade II or III meningioma patients (types of aggressive brain tumours), and found no improvement in progression free or overall survival for these patients. Results from this study can serve as a benchmark for future clinical trials investigating trabectedin.


Go to Top